Although the incidence of encephalitis associated with PD-1/PD-L1 inhibitors (e.g., pembrolizumab) is lower than that of CTLA-4 inhibitors, its prognosis can be poor when it occurs. This evidence concerns the gene CD274 and viral encephalitis.